Globalpharma, the UAE’s leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, has collaborated with India’s ZIM Laboratories to bring EU-certified Oral Dispersible Film (ODF) technology to its growing portfolio.
This innovative drug technology has already received EU Good Manufacturing Practice (EU-GMP) certification, ensuring it meets the highest international quality and safety standards.
The agreement, unveiled at AIM Congress 2025 (7-9 April), underscores the UAE’s growing influence in global pharmaceutical innovation and its commitment to cutting-edge healthcare solutions.
Commenting on the collaboration, Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries stated, “This partnership with ZIM Labs is a transformative step for Globalpharma. By bringing EU-certified ODF technology to the UAE, we are strengthening the region’s pharmaceutical capabilities and advancing patient-centric treatment options. This move aligns with our vision to invest in innovations that elevate regional healthcare standards while positioning the UAE as a leader in advanced drug manufacturing.”
ODFs represent a breakthrough in the drug industry, offering thin, fast-dissolving strips that melt in the mouth without water—ideal for children, elderly patients, and those with swallowing difficulties. ZIM Labs' proprietary technology enables the seamless incorporation of medications into these stable, rapid-acting films, enhancing patient compliance and treatment efficacy.
